Zynteglo

Zynteglo is a gene therapy treatment designed for people with beta-thalassemia, a genetic condition that reduces the body’s ability to make hemoglobin, leading to severe anemia. It works by inserting a healthy copy of the gene responsible for producing hemoglobin into the patient’s own stem cells. These modified cells are then returned to the body, where they start producing functional hemoglobin, potentially reducing or eliminating the need for blood transfusions. Zynteglo offers a potential long-term solution for eligible patients, aiming to restore normal blood function and improve quality of life.